Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral tablet for oral use. It is used to prevent organ rejection in patients who have undergone kidney, heart, or liver transplantation. GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic is an immunosuppressant that works by inhibiting lymphocyte proliferation, making it essential in transplant medicine.

Kidney transplantation: helps prevent acute and chronic rejection of the transplanted kidney. Heart transplantation: reduces the risk of graft rejection and improves long‑term graft survival. Liver transplantation: supports maintenance of graft function by suppressing immune‑mediated damage.

Myfortic may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often self‑limiting. - Vomiting: occasional episodes, especially early in therapy. - Abdominal pain: crampy discomfort in the stomach area. - Headache: transient, usually resolves without intervention. - Infections: increased susceptibility to bacterial, viral, or fungal infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells, raising infection risk. - Anemia: decreased red blood cell count leading to fatigue. - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Malignancy: heightened risk of lymphoproliferative disorders. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection.

Before initiating Myfortic, clinicians should assess patient-specific risk factors and monitor for adverse events. - Monitor blood counts: perform regular complete blood counts to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine clearance is reduced. - Screen for infections: evaluate for active infections and vaccinate appropriately before treatment. - Avoid in pregnancy: potential teratogenic effects; use effective contraception. - Store at room temperature: keep in the original container, protect from moisture and heat.

Myfortic interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Live vaccines: increased risk of vaccine‑derived infection. - Cholestyramine: binds drug and reduces absorption. - Rifampin: strong CYP3A4 inducer that lowers mycophenolic acid levels. - Antacids containing aluminum or magnesium: may decrease bioavailability.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance nephrotoxic potential. - NSAIDs: increase risk of renal impairment. - Warfarin: may affect INR and bleeding risk. - Ganciclovir: potential additive myelosuppression. - Diuretics: monitor electrolytes and renal function.